Ethyl 2- (4-Hydroxyphenyl) -4-Methylthiazole-5-Carboxylate CAS 161797-99-5 Febuxostat Purity Meadhanach> 99.0% Factaraidh
Solarachadh ceimigeach Ruifu Febuxostat eadar-mheadhanach co-cheangailte:
Febuxostat CAS 144060-53-7
Ethyl 2-Chloroacetoacetate CAS 609-15-4
4-Hydroxythiobenzamide CAS 25984-63-8
Ethyl 2- (3-Cyano-4-Hydroxyphenyl)-4-Methyl-1,3-Thiazole-5-Carboxylate CAS 161798-02-3
Ethyl 2- (3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5-Thiazolecarboxylate CAS 160844-75-7
Ethyl 2- (3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-01-2
Ethyl 2- (3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161798-03-4
Ethyl 2- (4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate CAS 161797-99-5
Ainm Ceimigeach | Ethyl 2- (4-Hydroxyphenyl)-4-Methylthiazole-5-Carboxylate |
Co-fhaclan | Febuxostat eadar-mheadhanach |
Àireamh CAS | 161797-99-5 |
Àireamh CAT | RF-PI1122 |
Inbhe Stoc | Ann an stoc, comas cinneasachaidh 100 tonna / bliadhna |
Foirmle Molecular | C13H13NO3S |
Cuideam Molecular | 263.31 |
Rubha leaghaidh | 180 ℃ |
Brand | Ceimigeach Ruifu |
Nì | Sònrachaidhean |
Coltas | Buidhe aotrom gu pùdar nach eil geal |
Aithneachadh | Le HPLC;Le HNMR |
Call air tiormachadh | <0.50% |
Fuigheall air Ighition | <0.30% |
Impurity singilte | <0.50% |
Neo-dhìomhaireachd iomlan | <1.00% |
Purity / Modh Mion-sgrùdadh | > 99.0% (le HPLC) |
Inbhe deuchainn | Inbhe Iomairt |
Cleachdadh | Eadar-mheadhanach de Febuxostat (CAS: 144060-53-7) |
Pacaid: Botal, poca foil alùmanum, 25kg / druma cairt-bhòrd, no a rèir riatanas luchd-ceannach
Suidheachadh stòraidh:Bùth ann an soithichean dùinte ann an àite fionnar is tioram;Dìon bho sholas is taiseachd
Tha Ethyl 2- (4-Hydroxyphenyl) -4-Methylthiazole-5-Carboxylate (CAS: 161797-99-5) air a chleachdadh ann an synthesis Febuxostat (CAS: 144060-53-7), inneal-dìon xanthine oxidase / xanthine dehydrogenase.Air a chleachdadh airson làimhseachadh hyperuricemia agus gout leantainneach.Chaidh 40-120 mg / day febuxostat a dhearbhadh gu h-èifeachdach ann a bhith a ’lughdachadh ìrean serum urate nuair a chaidh a thoirt seachad gus hyperuricemia a riaghladh ann an euslaintich le gout.Chaidh Fabuxostat a lorg le Teijin Pharmaceuticals agus chaidh a cheadachadh gu TAP Pharmaceuticals (a tha an-dràsta na phàirt de Takeda Pharmaceuticals) agus chaidh aontachadh anns na SA airson làimhseachadh hyperuricemia ann an euslaintich le gout.